Estimator | Estimator

This site is intended only for healthcare professionals residing in Singapore

Log Out

Our medicines

Therapy areas

Explore content

Events

Materials

Videos

Let’s connect

Pfizer medical information

AN EDUCATIONAL TOOL TO ESTIMATE THE PROBABILITY OF WILD-TYPE TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (wtATTR-CM)

Developed with AI/ML algorithm using diagnosis codes from a real-world claims dataset, the Estimator highlights different combinations of cardiac and non-cardiac symptoms of Wild-Type Transthyretin Amyloid Cardiomyopathy (wtATTR-CM) for hypothetical patient cases with heart failure.¹

Try out the Estimator tool to learn more about the red flags of wild-type ATTR-CM and the associated risk to help raise suspicion of this life-threatening disease.

Learn More

Huda A, Heitner S, Calambur V, et al. A machine learning framework for predicting risk of wild-type transthyretin amyloid cardiomyopathy. Poster presented at: XVII International Society of Amyloidosis Symposium; September 14-18, 2020; virtual.

PP-VDM-SGP-0189/20FEB2023

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Account

Sign Out

The information provided in this site is intended only for Healthcare Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Pte Ltd, Singapore is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.

You are now leaving the website

You are now leaving a Pfizer-operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.